Live feed08:00:00·136dPRReleaseFate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell ProgramsFATE· Fate Therapeutics Inc.Health CareOriginal source
